Wealth Enhancement Advisory Services LLC Buys 4,810 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Wealth Enhancement Advisory Services LLC raised its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 9.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 57,624 shares of the company’s stock after buying an additional 4,810 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.06% of ARS Pharmaceuticals worth $836,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its stake in ARS Pharmaceuticals by 14.8% in the 1st quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock valued at $110,999,000 after buying an additional 1,401,299 shares in the last quarter. Vanguard Group Inc. raised its position in ARS Pharmaceuticals by 37.0% in the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after purchasing an additional 779,969 shares during the last quarter. ClariVest Asset Management LLC raised its position in ARS Pharmaceuticals by 5.4% in the 2nd quarter. ClariVest Asset Management LLC now owns 287,596 shares of the company’s stock valued at $2,447,000 after purchasing an additional 14,640 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in ARS Pharmaceuticals by 1,280.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 277,706 shares of the company’s stock valued at $2,838,000 after purchasing an additional 257,589 shares during the last quarter. Finally, Raymond James & Associates bought a new position in ARS Pharmaceuticals in the 3rd quarter valued at $2,969,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on SPRY shares. Leerink Partners boosted their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.00.

ARS Pharmaceuticals Trading Up 2.6 %

SPRY opened at $15.72 on Thursday. ARS Pharmaceuticals, Inc. has a 52-week low of $3.38 and a 52-week high of $17.08. The business’s 50-day simple moving average is $14.12 and its 200 day simple moving average is $11.34.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $2.00 million. As a group, research analysts predict that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Brian Dorsey sold 50,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the sale, the chief operating officer now owns 6,024 shares of the company’s stock, valued at $90,360. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Kathleen D. Scott sold 12,500 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $16.00, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer now directly owns 4,949 shares of the company’s stock, valued at $79,184. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Brian Dorsey sold 50,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the transaction, the chief operating officer now directly owns 6,024 shares of the company’s stock, valued at approximately $90,360. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,055,895 shares of company stock valued at $14,619,032 over the last 90 days. 40.10% of the stock is owned by corporate insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.